In addition to the down-regulation of 5AR and AR, CA treatment also suppressed the level of ERα than the BPH group, which may suggest another potential action mechanism of CA besides the 5AR-AR axis. This evidence concerns the gene ESR1 and benign prostatic hyperplasia.